Medical device company, Medtronic, has announced the use of its Sugar.IQ app, the first-of-its-kind cognitive app that helps detect important patterns and trends for people with diabetes powered by IBM Watson.
Sugar.IQ uses real-time continuous glucose monitoring and insulin information from Medtronic pumps and glucose sensors. It leverages IBM Watson’s cognitive computing power, combined with Medtronic’s expertise in diabetes, to find hidden patterns in diabetes data.
Earlier this year, Medtronic and IBM unveiled their collaboration on the app and demonstrated the completed app at the 10th Annual Health 2.0 Fall Conference in California.
“We have made great progress in development of the Sugar.IQ app since unveiling the first research concepts at CES 2016,” said President of Diabetes Service and Solutions at Medtronic, Annette Brüls.
The app is designed to provide real-time and personalised insights on a single platform that brings together relevant data and provides context and insights, providing diabetics with answers about their current health status, where their health is trending, and what actions they can take to better manage their condition in the future.
The Sugar.IQ app can be used to uncover behaviours that influence glucose levels and send appropriate alerts to users. The app’s Glycaemic Assist feature enables users to inquire about how specific foods impact their personal glucose levels, and the software can track food to deliver meal-related insights to help people better control their diabetes.
During the launch of the Sugar.IQ app, the companies said they would offer a limited launch of the application to 100 users of Medtronic’s MiniMed Connect mobile accessory users to explore the design and usability of the app and provide feedback on their experience ahead of the app’s broader rollout later this year.
“Through our collaboration with IBM Watson Health, Medtronic will arm people with diabetes with a unique solution that could uncover previously unknown patterns while serving as a personal assistant that offers meaningful information when it matters to help transform diabetes care for greater freedom and better health,” concluded Brüls.